



ALLIANCE HEALTHCARE GROUP LIMITED

(Incorporated in the Republic of Singapore on 6 June 2006)
(UEN. 200608233K)

Alliance Healthcare Group Limited and its Subsidiaries

Registration Number: 200608233K

**Condensed Interim Financial Statements
For the six months ended 31 December 2025**

*This announcement has been reviewed by the Company's sponsor, RHB Bank Berhad (the "**Sponsor**") in accordance with Rule 226(2)(b) of the Catalist Rules. This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement. The contact person for the Sponsor is Mr Alvin Soh, Head, Corporate Finance, RHB Bank Berhad, at 90 Cecil Street, #03-00 RHB Bank Building, Singapore 069531, Telephone: +65 6320 0627.*



Table of Contents	Page
A. Condensed interim consolidated statement of profit or loss and other comprehensive income	1
B. Condensed interim statements of financial position	2
C. Condensed interim statements of changes in equity	3
D. Condensed interim consolidated statement of cash flows	5
E. Notes to the condensed interim financial statements	7
F. Other information required by Appendix 7C of the Catalist Rules	20

Reporting Period

Current Reporting Period: 6 months ended 31 December 2025 (“HY2026”)

Corresponding period of the immediately preceding financial year: 6 months ended 31 December 2024 (“HY2025”)



A. Condensed interim consolidated statement of profit or loss and other comprehensive income

		Group 6 months ended 31 December		Variance S\$	%
	Note	2025 S\$	2024 S\$		
Revenue	4	42,327,230	37,929,501	4,397,729	11.6
Interest income		2,290	3,663	(1,373)	(37.5)
Other income and gains		84,730	126,812	(42,082)	(33.2)
Consumables and medical supplies used		(9,837,347)	(10,213,737)	376,390	(3.7)
Employee benefits expense		(24,342,672)	(21,450,129)	(2,892,543)	13.5
Depreciation and amortisation expense		(2,535,013)	(2,324,334)	(210,679)	9.1
Other losses		(16,957)	(298)	(16,659)	n.m.
Finance costs		(325,704)	(477,292)	151,588	(31.8)
Other expenses		(3,610,510)	(3,253,670)	(356,840)	11.0
Share of results of an associate		93,649	(37,181)	130,830	n.m.
Profit before tax	6	1,839,696	303,335	1,536,361	n.m.
Income tax expense	7	(530,869)	(229,694)	(301,175)	131.1
Profit for the financial period, net of tax		1,308,827	73,641	1,235,186	n.m.
Other comprehensive income:					
<u>Items that may be reclassified subsequently to profit or loss:</u>					
Exchange differences on translating foreign operations, net of tax		10,665	10,647	18	0.2
Other comprehensive income for the period, net of tax		10,665	10,647	18	0.2
Total comprehensive income for the period		1,319,492	84,288	1,235,204	n.m.
Profit/(loss) attributable to:					
– Owners of the parent		1,523,151	292,100	1,231,051	n.m.
– Non-controlling interests		(214,324)	(218,459)	4,135	(1.9)
Profit for the financial period, net of tax		1,308,827	73,641	1,235,186	n.m.
Total comprehensive income/(loss) attributable to:					
– Owners of the parent		1,533,816	302,747	1,231,069	n.m.
– Non-controlling interests		(214,324)	(218,459)	4,135	(1.9)
Total comprehensive income for the period		1,319,492	84,288	1,235,204	n.m.

*n.m. denotes not meaningful



B. Condensed interim statements of financial position

		Group		Company	
	Note	31-Dec-25 S\$	30-Jun-25 S\$	31-Dec-25 S\$	30-Jun-25 S\$
ASSETS					
<u>Non-current assets</u>					
Property, plant and equipment	12	9,450,032	9,488,479	114,532	91,169
Right-of-use assets		5,415,177	6,194,738	90,735	9,981
Investment properties	13	-	-	4,343,274	4,412,766
Investment in subsidiaries		-	-	5,877,632	5,877,632
Investment in an associate		1,052,489	958,840	-	-
Intangible assets and goodwill	11	7,594,706	7,223,732	-	-
Trade and other receivables		416,667	566,667	416,667	566,667
Deferred tax assets		12,400	12,400	-	-
Total non-current assets		23,941,471	24,444,856	10,842,840	10,958,215
<u>Current assets</u>					
Inventories		4,209,144	4,066,833	-	-
Financial assets - derivatives		88,475	88,475	-	-
Trade and other receivables		45,541,548	44,992,354	28,240,264	24,567,774
Other non-financial assets		1,081,782	1,075,616	180,510	160,623
Cash and cash equivalents		19,013,902	16,403,846	2,057,001	1,401,229
Total current assets		69,934,851	66,627,124	30,477,775	26,129,626
Total assets		93,876,322	91,071,980	41,320,615	37,087,841
EQUITY AND LIABILITIES					
<u>Equity attributable to owners of the parent</u>					
Share capital	15	14,684,250	14,684,250	14,684,250	14,684,250
Treasury shares	15	(262,294)	(262,294)	(262,294)	(262,294)
Retained earnings		16,559,976	15,243,215	5,628,839	5,262,140
Other reserves		(5,242,078)	(5,294,091)	248,087	206,739
Equity, attributable to owners of the parent		25,739,854	24,371,080	20,298,882	19,890,835
Non-controlling interests		(646,987)	(308,163)	-	-
Total equity		25,092,867	24,062,917	20,298,882	19,890,835
<u>Non-current liabilities</u>					
Financial liabilities - lease liabilities		3,313,099	3,856,400	59,844	-
Loans and borrowings	14	5,556,904	6,513,717	2,863,900	3,425,249
Deferred tax liabilities		14,905	24,740	-	-
Total non-current liabilities		8,884,908	10,394,857	2,923,744	3,425,249
<u>Current liabilities</u>					
Income tax payable		298,207	31,820	-	-
Trade and other payables		51,010,731	48,160,437	15,744,621	12,073,882
Provision		415,125	403,500	-	-
Other non-financial liabilities		638,488	540,279	-	-
Financial liabilities - lease liabilities		2,943,068	3,147,604	31,138	10,344
Loans and borrowings	14	4,592,928	4,330,566	2,322,230	1,687,531
Total current liabilities		59,898,547	56,614,206	18,097,989	13,771,757
Total liabilities		68,783,455	67,009,063	21,021,733	17,197,006
Total equity and liabilities		93,876,322	91,071,980	41,320,615	37,087,841



C. Condensed interim statements of changes in equity

Group	Note	Total equity S\$	Attributable to owners of the parent					Non-controlling interests S\$
			Sub-total S\$	Share capital S\$	Treasury shares S\$	Retained earnings S\$	Other reserves S\$	
Opening balance at 1 July 2025		24,062,917	24,371,080	14,684,250	(262,294)	15,243,215	(5,294,091)	(308,163)
Changes in equity:								
Total comprehensive income/(loss) for the period		1,319,492	1,533,816	-	-	1,523,151	10,665	(214,324)
Performance Share Plan	6	41,348	41,348	-	-	-	41,348	-
Dividends paid	8	(206,390)	(206,390)	-	-	(206,390)	-	-
Dividends paid to non-controlling interests in subsidiaries		(124,500)	-	-	-	-	-	(124,500)
Closing balance at 31 December 2025		25,092,867	25,739,854	14,684,250	(262,294)	16,559,976	(5,242,078)	(646,987)
Opening balance at 1 July 2024		23,005,668	22,736,509	14,684,250	(336,338)	13,719,205	(5,330,608)	269,159
Changes in equity:								
Total comprehensive income/(loss) for the period		84,288	302,747	-	-	292,100	10,647	(218,459)
Performance Share Plan	6	47,600	47,600	-	-	-	47,600	-
Dividends paid to non-controlling interests in subsidiaries		(84,500)	-	-	-	-	-	(84,500)
Closing balance at 31 December 2024		23,053,056	23,086,856	14,684,250	(336,338)	14,011,305	(5,272,361)	(33,800)



C. Condensed interim statements of changes in equity (cont'd)

Company	Note	Total equity S\$	Share capital S\$	Treasury shares S\$	Retained earnings S\$	Other reserves S\$
Opening balance at 1 July 2025		19,890,835	14,684,250	(262,294)	5,262,140	206,739
Changes in equity:						
Total comprehensive income for the period		573,089	-	-	573,089	-
Performance Share Plan	6	41,348	-	-	-	41,348
Dividends paid	8	(206,390)	-	-	(206,390)	-
Closing balance at 31 December 2025		20,298,882	14,684,250	(262,294)	5,628,839	248,087
Opening balance at 1 July 2024		19,012,515	14,684,250	(336,338)	4,479,494	185,109
Changes in equity:						
Total comprehensive loss for the period		(243,900)	-	-	(243,900)	-
Performance Share Plan	6	47,600	-	-	-	47,600
Closing balance at 31 December 2024		18,816,215	14,684,250	(336,338)	4,235,594	232,709



D. Condensed interim consolidated statement of cash flows

		Group	
		6 months ended 31 December	
	Note	2025 S\$	2024 S\$
<u>Cash flows from operating activities</u>			
Profit before tax		1,839,696	303,335
Adjustments for:			
Performance share plan expense		41,348	47,600
Depreciation of property, plant and equipment		704,940	714,910
Depreciation of right-of-use assets		1,630,202	1,534,834
Amortisation of intangible assets		199,871	74,590
Gain on disposal of property, plant and equipment		(4,541)	-
Gain on disposal of right-of-use assets		-	(2,256)
Interest expense		199,544	320,816
Lease interest expense		126,160	156,476
Interest income		(2,290)	(3,663)
Share of results of an associate		(93,649)	37,181
Operating cash flows before changes in working capital		4,641,281	3,183,823
<u>Changes in working capital:</u>			
Inventories		(142,311)	(42,930)
Trade and other receivables		(399,194)	(1,478,398)
Other non-financial assets		(6,166)	100,861
Trade and other payables		2,922,364	2,051,482
Other non-financial liabilities		98,209	90,269
Net effect of exchange rate changes in consolidating foreign operations		9,732	7,239
Net cash flows from operations		7,123,915	3,912,346
Income tax paid		(274,317)	(228,268)
Net cash flows from operating activities		6,849,598	3,684,078
<u>Cash flows from investing activities</u>			
Interest received		2,290	3,663
Loan to an associate		-	(135,000)
Purchase of property, plant and equipment	12	(536,992)	(398,461)
Additions to intangible assets	11	(570,845)	(578,100)
Net cash flows used in investing activities		(1,105,547)	(1,107,898)



D. Condensed interim consolidated statement of cash flows (cont'd)

	Group	
	6 months ended 31 December	
Note	2025 S\$	2024 S\$
<u>Cash flows from financing activities</u>		
Lease liabilities – principal and interest paid	(1,767,893)	(1,643,050)
Movements in amount due to related parties	199,940	93,957
Proceeds from loans and borrowings	450,000	335,013
Repayments of loans and borrowings	(1,374,391)	(1,391,161)
Finance lease repayments	(111,217)	(79,947)
Dividends paid to equity holders of the Company	(206,390)	-
Dividends paid to non-controlling interests	(124,500)	(84,500)
Interest paid	(199,544)	(320,816)
Net cash flows used in financing activities	(3,133,995)	(3,090,504)
Net increase/(decrease) in cash and cash equivalents	2,610,056	(514,324)
Cash and cash equivalents, statement of cash flows, beginning balance	16,325,846	18,570,852
Cash and cash equivalents, statement of cash flows, ending balance ⁽¹⁾	18,935,902	18,056,528

Note (1):

For the purpose of presenting the consolidated statement of cash flows, cash and cash equivalents comprise the following:

	Group	
	31 December	
	2025 S\$	2024 S\$
Cash and cash equivalents per condensed interim statement of financial position – Group	19,013,902	18,134,528
Less: Bank deposits pledged (a)	(78,000)	(78,000)
Cash and cash equivalents per consolidated statement of cash flows	18,935,902	18,056,528

(a) Bank deposits are pledged as security for merchant agreement between the bank and the group.



E. Notes to the condensed interim financial statements

1. Corporate information

Alliance Healthcare Group Limited (the “**Company**”) is incorporated in Singapore with limited liability. These condensed interim financial statements as at and for the six months ended 31 December 2025 comprise the Company (referred to as “**parent**”) and its subsidiaries (collectively, the “**Group**”).

The principal activities of the Group are:

- a) investment holding company and provision of administrative and management services;
- b) the provision of managed healthcare solutions;
- c) the wholesale of pharmaceutical products;
- d) the provision of medical services; and
- e) the provision of mobile and digital health services.

2. Basis of preparation

The condensed interim financial statements for the six months ended 31 December 2025 have been prepared in accordance with the Singapore Financial Reporting Standards (International) SFRS(I) 1-34 *Interim Financial Reporting* issued by the Accounting Standards Council Singapore. The condensed interim financial statements do not include all the information required for a complete set of financial statements. However, selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Group's financial position and performance of the Group since the last annual financial statements for the year ended 30 June 2025.

The accounting policies adopted are consistent with those of the previous financial year which were prepared in accordance with SFRS(I)s, except for the adoption of new and amended standards as set out in Note 2.1.

The condensed interim financial statements are presented in Singapore dollar which is the Company's functional currency.

2.1 New and amended standards adopted by the Group

A number of amendments to Standards have become applicable for the current reporting period. The Group did not have to change its accounting policies or make retrospective adjustments as a result of adopting those standards.

2.2 Use of judgements and estimates

In preparing the condensed interim financial statements, management has made judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from these estimates.

The significant judgements made by management in applying the Group's accounting policies and the key sources of estimation uncertainty were the same as those that applied to the audited consolidated financial statements as at and for the year ended 30 June 2025.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimates are revised and in any future periods affected.



2.2 Use of judgements and estimates (cont'd)

Information about critical judgements in applying accounting policies that have the most significant effect on the amounts recognised in the condensed interim financial statements is included in the following note:

- Note 11.1 – Assessment of impairment of goodwill

Information about assumptions and estimation uncertainties that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next interim period are included in the following note:

- Note 11.1 – Impairment test of goodwill: key assumptions underlying recoverable amounts

3. Seasonal operations

The Group's businesses are not affected significantly by seasonal or cyclical factors.

4. Segment and revenue information

For management purposes, the reporting entity is organised into the following major strategic operating segments that offer different products and services:

- 1) GP clinic services;
- 2) Specialist care services;
- 3) Managed healthcare solutions;
- 4) Pharmaceutical services;
- 5) Mobile and digital health services; and
- 6) Others.

These operating segments are reported in a manner consistent with internal reporting provided to Dr. Barry Thng Lip Mong, Chief Executive Officer, who is responsible for allocating resources and assessing performance of the operating segments.



4. Segment and revenue information (cont'd)

4.1 Reportable segments

	6 months ended 31 December 2025							
	GP clinic services S\$	Specialist care services S\$	Managed healthcare solutions S\$	Pharmaceuti- cal services S\$	Mobile and digital health services S\$	Others S\$	Eliminations S\$	Group S\$
Revenue by segment								
External sales	10,183,760	9,371,952	10,428,079	7,153,034	3,718,955	1,471,450	-	42,327,230
Inter-segment sales	471,306	-	266,535	1,733,038	114,898	3,583,417	(6,169,194)	-
Total revenue	10,655,066	9,371,952	10,694,614	8,886,072	3,833,853	5,054,867	(6,169,194)	42,327,230
EBITDA								
Finance costs	(118,820)	(62,085)	(13,050)	(21,858)	(107,496)	(2,395)	-	(325,704)
Depreciation and amortisation	(1,096,781)	(756,791)	(201,044)	(251,634)	(146,411)	(82,352)	-	(2,535,013)
Share of results of an associate	-	-	-	-	93,649	-	-	93,649
Profit/(loss) before tax	660,134	(112,074)	1,439,388	602,415	(222,428)	(527,739)	-	1,839,696
Income tax expense								(530,869)
Profit, net of tax								1,308,827
Segment assets								
	16,759,836	8,329,176	64,626,622	9,368,705	7,018,696	31,302,033	(43,528,746)	93,876,322
Segment liabilities								
	(9,423,200)	(8,152,005)	(49,733,294)	(4,216,416)	(14,275,961)	(20,714,737)	37,732,158	(68,783,455)
Other material items and reconciliations								
Expenditures for property, plant and equipment, and intangible assets	34,684	141,080	616,432	226,515	163,481	54,535	-	1,236,727



4. Segment and revenue information (cont'd)

4.1 Reportable segments (cont'd)

	6 months ended 31 December 2024							
	GP clinic services S\$	Specialist care services S\$	Managed healthcare solutions S\$	Pharmaceuti- cal services S\$	Mobile and digital health services S\$	Others S\$	Eliminations S\$	Group S\$
Revenue by segment								
External sales	9,175,699	8,282,827	8,403,572	8,372,470	2,792,414	902,519	-	37,929,501
Inter-segment sales	18,346	-	262,275	1,766,130	136,093	2,850,307	(5,033,151)	-
Total revenue	9,194,045	8,282,827	8,665,847	10,138,600	2,928,507	3,752,826	(5,033,151)	37,929,501
EBITDA	1,270,970	669,842	1,245,063	1,303,189	(589,445)	(757,477)	-	3,142,142
Finance costs	(190,072)	(67,173)	(2,630)	(32,636)	(94,414)	(90,367)	-	(477,292)
Depreciation and amortisation	(1,077,144)	(627,845)	(100,415)	(230,956)	(155,534)	(132,440)	-	(2,324,334)
Share of results of an associate	-	-	-	-	(37,181)	-	-	(37,181)
Profit/(loss) before tax	3,754	(25,176)	1,142,018	1,039,597	(876,574)	(980,284)	-	303,335
Income tax expense								(229,694)
Profit, net of tax								73,641
Segment assets	16,792,571	8,224,883	42,044,548	9,468,482	6,582,984	33,692,182	(33,082,888)	83,722,762
Segment liabilities	(10,131,440)	(7,733,696)	(38,351,180)	(4,272,523)	(12,960,147)	(14,875,969)	27,655,249	(60,669,706)
Other material items and reconciliations								
Expenditures for property, plant and equipment, and intangible assets	48,431	196,102	518,158	86,997	110,355	16,518	-	976,561



4. Segment and revenue information (cont'd)

4.2 Disaggregation of revenue

	Group 6 months ended 31 December 2025						
	GP clinic services S\$	Specialist care services S\$	Managed healthcare solutions S\$	Pharmaceutical services S\$	Mobile and digital health services S\$	Others S\$	Group S\$
<u>By nature</u>							
Rendering of services							
– Medical services	10,183,760	9,371,952	-	-	-	-	19,555,712
– Managed healthcare solutions services	-	-	10,428,079	-	-	-	10,428,079
– Mobile and digital health services	-	-	-	-	3,718,955	-	3,718,955
Sales of goods	-	-	-	7,153,034	-	-	7,153,034
Others	-	-	-	-	-	1,471,450	1,471,450
Total revenue	10,183,760	9,371,952	10,428,079	7,153,034	3,718,955	1,471,450	42,327,230
<u>By timing of revenue recognition</u>							
At a point in time	10,183,760	9,371,952	10,428,079	7,153,034	3,718,955	214,723	41,070,503
Over time	-	-	-	-	-	1,256,727	1,256,727
Total revenue	10,183,760	9,371,952	10,428,079	7,153,034	3,718,955	1,471,450	42,327,230
<u>By geography</u>							
Singapore	10,183,760	9,371,952	10,425,327	6,310,230	3,718,955	1,471,450	41,481,674
Others ⁽¹⁾	-	-	2,752	842,804	-	-	845,556
Total revenue	10,183,760	9,371,952	10,428,079	7,153,034	3,718,955	1,471,450	42,327,230

(1) "Others" include countries from Asia-Pacific, Europe and North America regions.



4. Segment and revenue information (cont'd)

4.2 Disaggregation of revenue (cont'd)

	Group 6 months ended 31 December 2024						
	GP clinic services S\$	Specialist care services S\$	Managed healthcare solutions S\$	Pharmaceutical services S\$	Mobile and digital health services S\$	Others S\$	Group S\$
<u>By nature</u>							
Rendering of services							
– Medical services	9,175,699	8,282,827	-	-	-	-	17,458,526
– Managed healthcare solutions services	-	-	8,403,572	-	-	-	8,403,572
– Mobile and digital health services	-	-	-	-	2,792,414	-	2,792,414
Sales of goods	-	-	-	8,372,470	-	-	8,372,470
Others	-	-	-	-	-	902,519	902,519
Total revenue	9,175,699	8,282,827	8,403,572	8,372,470	2,792,414	902,519	37,929,501
<u>By timing of revenue recognition</u>							
At a point in time	9,175,699	8,282,827	8,403,572	8,372,470	2,792,414	87,489	37,114,471
Over time	-	-	-	-	-	815,030	815,030
Total revenue	9,175,699	8,282,827	8,403,572	8,372,470	2,792,414	902,519	37,929,501
<u>By geography</u>							
Singapore	9,175,699	8,282,827	8,401,106	7,367,466	2,792,414	902,519	36,922,031
Others ⁽¹⁾	-	-	2,466	1,005,004	-	-	1,007,470
Total revenue	9,175,699	8,282,827	8,403,572	8,372,470	2,792,414	902,519	37,929,501

(1) "Others" include countries from Asia-Pacific, Europe and North America regions.



5. Financial assets and financial liabilities

Set out below is an overview of the financial assets and financial liabilities of the Group and the Company as at 31 December 2025 and 30 June 2025:

	Group		Company	
	31-Dec-25	30-Jun-25	31-Dec-25	30-Jun-25
	S\$	S\$	S\$	S\$
Financial Assets:				
Financial assets at amortised cost	64,972,118	61,962,867	30,713,932	26,535,670
Financial assets at fair value through profit or loss	88,475	88,475	-	-
Total	65,060,593	62,051,342	30,713,932	26,535,670
Financial Liabilities:				
Financial liabilities at amortised cost	67,416,730	66,008,724	21,021,733	17,197,006
Total	67,416,730	66,008,724	21,021,733	17,197,006

6. Profit before taxation

6.1 Significant items

	Group	
	6 months ended 31 December	
	2025	2024
	S\$	S\$
<u>Income</u>		
Other income	-	3,486
Government grants	28,966	70,740
Interest income	2,290	3,663
Reversal of allowance for impairment on trade receivables	-	676
Foreign exchange transaction gains	51,223	49,654
Gain on disposal of property, plant and equipment	4,541	-
Gain on disposal of right-of-use assets	-	2,256
<u>Expenses</u>		
Interest expense	(199,544)	(320,816)
Lease interest expense	(126,160)	(156,476)
Amortisation of intangible assets	(199,871)	(74,590)
Depreciation of property, plant and equipment	(704,940)	(714,910)
Depreciation of right-of-use assets	(1,630,202)	(1,534,834)
Performance share plan expense ⁽¹⁾	(41,348)	(47,600)
Bad debts written off trade receivables	(16,957)	(298)

Notes:

- (1) Performance share plan expense related to the value of employee services recognised for Group's performance shares awarded on 3 January 2023 to certain employees of the Group pursuant to the Alliance Healthcare Group Performance Share Plan 2022.



6. Profit before taxation (cont'd)

6.2 Related party transactions

There are transactions and arrangements between the Group and related parties and the effects of these on the basis determined between the parties are reflected in these financial statements.

	Group	
	6 months ended 31 December	
	2025	2024
	S\$	S\$
<u>An associate:</u>		
Administrative fees income	30,000	24,000
Interest income	27,361	34,391
Marketing fee income	21,000	21,000
Software subscription, maintenance and system enhancement	(46,776)	(37,450)
Outsourced manpower expenses	(614,880)	(324,720)
<u>Related parties:</u>		
Professional fees expenses	(2,996,102)	(3,145,751)
Payments in respect of a lease for premises	-	(17,810)

The professional fee expenses were paid/payable to entities in which certain directors of the company's subsidiaries have interest, or to a shareholder of one of the company's subsidiaries.

7. Taxation

The Group calculates the period income tax expense using the tax rate that would be applicable to the expected total annual earnings. The major components of income tax expense in the condensed interim consolidated statement of profit or loss are:

	Group	
	6 months ended 31 December	
	2025	2024
	S\$	S\$
<u>Current tax expense/(credit):</u>		
Current tax expense	547,661	496,001
Adjustments in respect of prior periods	(6,957)	(253,579)
Subtotal	540,704	242,422
<u>Deferred tax income:</u>		
Deferred tax income	(9,835)	(12,728)
Subtotal	(9,835)	(12,728)
Total income tax expense	530,869	229,694



8. Dividends

	Company	
	6 months ended 31 December	
	2025	2024
	S\$	S\$
Ordinary dividends paid:		
First & final one-tier tax-exempt dividend paid	206,390	-
Dividend per share (net of tax)	0.001	-

9. Earnings per share

	Group	
	6 months ended 31 December	
	2025	2024
Earnings attributable to equity holders of the Company (S\$)	1,523,151	292,100
Weighted average number of Shares used in computation of basic earnings per share ("EPS")	206,390,352	205,962,352
Basic EPS attributable to equity holders of the Company (cents) ⁽¹⁾	0.74	0.14
Fully diluted EPS attributable to equity holders of the Company (cents) ⁽²⁾	0.74	0.14

Notes:

- (1) Basic EPS is computed by dividing the Group's earnings attributable to the equity holders of the Company in each financial period by the weighted average number of Shares outstanding during the respective financial period.
- (2) Fully diluted EPS are the same as the basic EPS for the financial periods presented in the table above as the Company did not have any outstanding instruments convertible into rights to subscribe for, and options in respect of its Shares during these financial periods.

10. Net asset value per share

	Group		Company	
	31-Dec-25	30-Jun-25	31-Dec-25	30-Jun-25
Net asset value attributable to owners of the parent ("NAV") per ordinary share (cents)	12.47	11.81	9.84	9.64
Number of Shares used in computation of NAV	206,390,352	206,390,352	206,390,352	206,390,352

Net asset value attributable to owners of the parent (for the Company and the Group) per ordinary share are computed based on the total number of issued shares (excluding treasury shares, if any) as at the end of the relevant financial period.



11. Intangible assets

	Group				
	Goodwill	Customer relationship	Unpatented technology	System development	Total
	S\$	S\$	S\$	S\$	S\$
At 30 June 2025					
Cost	5,190,858	131,027	810,000	1,988,199	8,120,084
Accumulated amortisation	-	(131,027)	(636,429)	(128,896)	(896,352)
Net book amount	5,190,858	-	173,571	1,859,303	7,223,732
6 months ended 31 December 2025					
Opening net book amount	5,190,858	-	173,571	1,859,303	7,223,732
Additions	-	-	-	570,845	570,845
Amortisation charge	-	-	(57,857)	(142,014)	(199,871)
Closing net book amount	5,190,858	-	115,714	2,288,134	7,594,706
At 31 December 2025					
Cost	5,190,858	131,027	810,000	2,559,044	8,690,929
Accumulated amortisation	-	(131,027)	(694,286)	(270,910)	(1,096,223)
Net book amount	5,190,858	-	115,714	2,288,134	7,594,706

11.1 Goodwill impairment

Goodwill is allocated to cash-generating units ("CGU") for the purpose of impairment testing. Each of those CGUs the Group's investment in the following subsidiaries:

	Group	
	31-Dec-2025	30-Jun-2025
	S\$	S\$
<u>Name of subsidiaries:</u>		
"My Family Clinic"		
Alliance Medical Group Pte. Ltd. ^(a)	1,101,541	1,101,541
My Family Clinic (PN) Pte. Ltd.	128,951	128,951
My Family Clinic (Hougang Central) Pte. Ltd.	780,000	780,000
My Family Clinic (Clementi 325) Pte. Ltd.	596,071	596,071
Sub-total	2,606,563	2,606,563
Jaga-Me Pte. Ltd.	2,584,295	2,584,295
Sub-total	2,584,295	2,584,295
Total	5,190,858	5,190,858

(a) Alliance Medical Group Pte Ltd is an investment holding company that holds entities that operate under "My Family Clinic".

The Group performed its annual impairment test in June 2025. The key assumptions used to determine the recoverable amount for the CGU were disclosed in note 18 of the audited consolidated financial statements for the financial year ended 30 June 2025.

12. Property, plant and equipment

During the six months ended 31 December 2025, the Group acquired assets amounting to S\$666,000 (31 December 2024: S\$398,000), of which S\$124,000 (31 December 2024: nil) was settled via hire purchase and S\$5,000 (31 December 2024: nil) through the trade-in of an older vehicle, and disposed of assets with carrying value of \$459 (31 December 2024: nil).

13. Investment properties

The Group does not have any investment properties.

In the Company's balance sheet, the leasehold properties located at 25 Bukit Batok Crescent, Singapore 658066, are classified as investment properties as they are mostly leased out to subsidiaries. However, in the Group's consolidated balance sheet, these leasehold properties are classified as property, plant and equipment.

	Company	
	2025	2024
	S\$	S\$
<u>Cost:</u>		
At 1 July and 31 December	5,683,069	5,683,069
<u>Accumulated depreciation:</u>		
At 1 July	1,270,303	1,131,318
Depreciation for the period	69,492	69,492
At 31 December	1,339,795	1,200,810
<u>Carrying value:</u>		
At 31 December	4,343,274	4,482,259

14. Loans and borrowings and lease liabilities under finance leases

Loans and borrowings

	Group			
	31-Dec-25		30-Jun-25	
	Secured	Unsecured	Secured	Unsecured
	S\$	S\$	S\$	S\$
Amount repayable in one year or less, or on demand	2,285,204	2,307,724	2,312,948	2,017,618
Amount repayable after one year	3,974,102	1,582,802	4,603,178	1,910,539
Total	6,259,306	3,890,526	6,916,126	3,928,157

Details of loans and borrowings and their collaterals, if any:

As at 31 December 2025, the Group's bank borrowings amounted to S\$8.8 million (30 June 2025: S\$9.8 million), of which S\$6.3 million (30 June 2025: S\$6.9 million) are secured by legal mortgage of the Group's leasehold properties, a charge over certain receivables in respective of financed debts and guarantee provided by the Company.

As at 31 December 2025, loans from related parties amounted to S\$1.3 million (30 June 2025: S\$1.1 million) are unsecured, interest-free and repayable on demand.



14. Loans and borrowings and lease liabilities under finance leases (cont'd)

Lease liabilities under finance leases

As at 31 December 2025, the Group's lease liabilities under finance leases, amounting to S\$583,000 (30 June 2025: S\$540,000), are secured on the equipment and motor vehicles under finance leases and guarantees provided by the Company and a minority shareholder of a subsidiary.

15. Share capital and treasury shares

(a) Share capital

	Group and Company			
	31-Dec-2025		30-Jun-2025	
	Number of shares	S\$	Number of shares	S\$
Issued and fully paid ordinary shares				
Beginning & end of the period	207,888,352	14,684,250	207,888,352	14,684,250

There was no change in the Company's share capital between 30 June 2025 (being the end of the previous period reported on) and 31 December 2025.

The Company did not have any outstanding options or convertible instruments as at 31 December 2025 and 31 December 2024 (being the end of corresponding period of the immediately preceding financial year), save for outstanding share awards to take up unissued ordinary shares in the Company under the Alliance Healthcare Group Performance Share Plan 2022, amounting to 1,498,000 shares as at 31 December 2025 (31 December 2024: 1,926,000).

The Company's subsidiaries did not hold any shares in the Company as at 31 December 2025 and 31 December 2024 (being the end of corresponding period of the immediately preceding financial year).

(b) Treasury shares

	Group and Company			
	31-Dec-2025		31-Dec-2024	
	Number of shares	S\$	Number of shares	S\$
Beginning & end of the period	1,498,000	262,294	1,926,000	336,338
As a percentage of total number of issued shares excluding treasury shares	0.73%		0.94%	

There was no change in the Company's treasury shares between 30 June 2025 (being the end of the previous period reported on) and 31 December 2025.

	Group and Company		
	31-Dec-2025	30-Jun-2025	31-Dec-2024
Total number of issued shares excluding treasury shares	206,390,352	206,390,352	205,962,352



16. Acquisition or incorporation of subsidiaries without a change in control

There is no acquisition, incorporation, and/or sale of shares in any subsidiaries of the Group since 30 June 2025 (being the end of the previous period reported on) and up to 31 December 2025.

17. Acquisition of an associate

There was no change in the Company's investment in an associate between 30 June 2025 (being the end of the previous period reported on) and 31 December 2025.

18. Subsequent events

There are no subsequent events to be disclosed or which would have led to adjustments to this set of unaudited interim financial statements.



F. Other information required by Appendix 7C of the Catalyst Rules

1A. Whether the figures have been audited or reviewed, and in accordance with which auditing standard or practice.

The condensed interim financial statements of Alliance Healthcare Group Limited (the “**Company**”) and its subsidiaries (the “**Group**”), which comprise the condensed interim consolidated statement of financial position of the Group and the condensed interim statement of financial position of the Company as at 31 December 2025, the condensed interim consolidated statement of profit or loss and other comprehensive income, condensed interim consolidated statement of changes in equity, condensed interim statement of changes in equity of the Company and condensed interim consolidated statement of cash flows for the six-month period then ended, and notes to the financial statements have not been audited or reviewed.

1B. Where the figures have been audited or reviewed, the auditors’ report (including any modifications or emphasis of a matter).

Not applicable.

1C. Where the latest financial statements are subject to an adverse opinion, qualified opinion or disclaimer of opinion:

- (a) Updates on the efforts taken to resolve each outstanding audit issue.
- (b) Confirmation from the Board that the impact of all outstanding audit issues on the financial statements have been adequately disclosed.

This is not required for any audit issue that is a material uncertainty relating to going concern.

Not applicable.

2. Review of performance of the Group

Review of financial performance of the Group for HY2026 compared to HY2025

Revenue

Revenue increased by approximately S\$4.4 million or 11.6% from S\$37.9 million in HY2025 to S\$42.3 million in HY2026.

The overall increase in the Group’s revenue was mainly attributable to the following:

(a) Managed Healthcare Solutions

Revenue from managed healthcare solutions business segment increased by approximately S\$2.0 million or 23.8% from S\$8.4 million in HY2025 to S\$10.4 million in HY2026, mainly due to more programs established with business partners, higher patient volume and more corporate clients engaged.

(b) Specialist Care Services

Revenue from specialist care services increased by approximately S\$1.1 million or 13.3% from S\$8.3 million in HY2025 to S\$9.4 million in HY2026. The increase was mainly attributable to contributions from the Group’s second orthopaedic clinic and its Breast and General Surgery clinic, which commenced operations in May 2025 and September 2025, respectively (the “**New Specialist Clinics**”).



2. Review of performance of the Group (cont'd)

Review of financial performance of the Group for HY2026 compared to HY2025 (cont'd)

(c) Mobile and Digital Health Services

Revenue from mobile and digital health services increased by approximately S\$0.9 million or 32.1% from S\$2.8 million in HY2025 to S\$3.7 million in HY2026. The increase was mainly attributable to higher revenue from digital health services driven by increased demand for telemedicine services as the managed healthcare solutions business segment established more programs, as well as higher revenue from mobile health services arising from increased case volumes under the Mobile Inpatient Care at Home (“**MIC@Home**”) programme, as it became more widely adopted by restructured hospitals.

(d) GP Clinic Services

Revenue from GP clinic services increased by approximately S\$1.0 million or 10.9% from S\$9.2 million in HY2025 to S\$10.2 million in HY2026, mainly due to contributions from the Group’s medical centre and higher demand for our GP services, resulting from our continued efforts to support the Healthier SG initiative.

(e) Pharmaceutical Services

Revenue from pharmaceutical services decreased by approximately S\$1.2 million or 14.3% from S\$8.4 million in HY2025 to S\$7.2 million in HY2026. The decrease was mainly attributable to lower sales arising from the conclusion of certain supply arrangements with customers and the absence of non-recurring and ad-hoc orders that were recorded in HY2025.

(f) Others

Revenue from others increased by approximately S\$0.6 million or 66.7% from S\$0.9 million in HY2025 to S\$1.5 million in HY2026. This increase was mainly attributable to income from the Health Promotion Board (“**HPB**”) contract awarded in the last quarter of FY2024, which involves the supply, customisation, and maintenance of a clinic management system (“**CMS**”) for HPB’s Youth Preventive Service Division (“**YHCMS**”). Phase one of the CMS was launched in June 2025, with maintenance service commencing in September 2025. Phase two of the CMS went live in October 2025, seven months ahead of the original scheduled launch of June 2026, followed by the early commencement of phase two maintenance.

Interest income

The interest income from fixed deposits was not significant in HY2026 and HY2025.

Other income and gains

Other income and gains, mainly consisting of government grants, incentives and foreign exchange gains, decreased by S\$42,000 mainly due to less government grants received during HY2026.



2. Review of performance of the Group (cont'd)

Review of financial performance of the Group for HY2026 compared to HY2025 (cont'd)

Consumables and medical supplies used

Consumables and medical supplies used mainly relate to the Group's pharmaceutical services, GP clinic services, specialist care services, corporate clinics under the managed healthcare solutions segment and mobile and digital health services business segment.

Consumables and medical supplies used decreased by approximately S\$0.4 million or 3.7% from S\$10.2 million in HY2025 to S\$9.8 million in HY2026, mainly due to a decrease in consumables and medical supplies sold by the pharmaceutical services segment, partially offset by an increase of consumables and medical supplies used by the other business segments in line with the increase in their revenue.

Employee benefits expense

Employee benefits expense relates to salaries, bonuses, benefits, fees and other payments made to (i) the Group's employees, (ii) doctors (including locum and full-time GP doctors who may not be employees), (iii) nurses (including locum and full-time nurses who may not be employees), (iv) specialists with whom the Group has entered into contracts for provision of medical services and (v) outsourced IT personnel. In respect of such doctors (except for locum doctors who are paid on an hourly basis) and specialists with whom the Group entered into contracts, the fees are generally determined based on a base salary and/or the profitability of the relevant clinic.

Employee benefits expense increased by approximately S\$2.9 million or 13.5% from S\$21.4 million in HY2025 to S\$24.3 million in HY2026, mainly due to the following:

- (a) staff and related costs for the New Specialist Clinics which commenced operations in May 2025 and September 2025;
- (b) an increase in staff and related costs arising from increased headcount of employees and doctors to support the increased business activities in managed healthcare solutions and GP clinic services;
- (c) staff and related costs for the YHCMS contract to bring phase two's launch date seven months ahead of the original scheduled launch of June 2026; and
- (d) incremental staffing costs driven by general inflation.

Depreciation and amortisation expense

Depreciation and amortisation expense increased by approximately S\$0.2 million or 9.1%, from S\$2.3 million in HY2025 to S\$2.5 million in HY2026, mainly due to the following:

- (a) depreciation of additional right-of-use ("ROU") assets resulting from leases for the New Specialist Clinics which commenced operations in May 2025 and September 2025; and
- (b) amortisation of system development costs relating to certain in-house built platforms and systems, following their readiness for use.



2. Review of performance of the Group (cont'd)

Review of financial performance of the Group for HY2026 compared to HY2025 (cont'd)

Other losses

Other losses were not significant in HY2026 and HY2025.

Finance costs

Finance costs decreased by approximately S\$0.2 million or 31.8% from S\$0.5 million in HY2025 to S\$0.3 million in HY2026, due to lower outstanding loan balances and the decrease in interest rates during the period.

Other expenses

Other expenses increased by approximately S\$0.3 million or 11.0% from S\$3.3 million in HY2025 to S\$3.6 million in HY2026, mainly due to operating expenses in relation to the New Specialist Clinics, higher server and computer system expenses to support the increased managed healthcare solutions business and higher distribution costs in line with increased revenue from mobile and digital health services.

Share of results of an associate

The Group recorded a share of profit of approximately S\$94,000 from an associate in HY2026, compared to a share of loss of approximately S\$37,000 in HY2025, as the associate generated a profit in HY2026.

Profit before tax

As a result of the above, profit before tax increased by approximately S\$1.5 million from S\$0.3 million in HY2025 to S\$1.8 million in HY2026.

Income tax

The Group recorded a tax expense of approximately S\$0.5 million in HY2026 compared to a tax expense of approximately S\$0.2 million in HY2025, in line with higher profit before tax in HY2026.

Net profit attributable to owners of the parent

As a result of the above, net profit attributable to equity holders of the Company increased by approximately S\$1.2 million from S\$0.3 million in HY2025 to S\$1.5 million in HY2026.



2. Review of performance of the Group (cont'd)

Review of financial performance of the Group for HY2026 compared to HY2025 (cont'd)

Financial performance by operating segments

Revenue contribution by business segments:

	GP clinic services	Specialist care services	Managed healthcare solutions	Pharmaceutical services	Mobile and digital health services	Others
HY2026	24.1%	22.1%	24.6%	16.9%	8.8%	3.5%
HY2025	24.2%	21.8%	22.1%	22.1%	7.4%	2.4%

Compared to HY2025, the Group's net profit before tax increased mainly due to the following movements by business segment:

- (a) increased net profit before tax for GP clinic services, mainly due to narrowed losses from the Group's medical centre attributable to higher sales, as well as higher profit before tax from other GP clinics benefited from the Healthier SG initiative;
- (b) increased net profit before tax for managed healthcare solutions mainly due to higher revenue attributable to more programs established with business partners, higher patient volume and more corporate clients engaged;
- (c) narrowed loss before tax from mobile and digital health services as revenue increased from telemedicine services and MIC@Home;
- (d) narrowed loss before tax from others mainly due to positive contribution from the Group's YHCMS contract;
- (e) decreased net profit before tax for pharmaceutical services mainly due to lower sales arising from the conclusion of certain supply arrangements with customers and the absence of non-recurring and ad-hoc orders recorded in the previous corresponding period; and
- (f) increase net loss before tax from specialist care services, mainly due to the operating costs and depreciation expenses incurred by the New Specialist Clinics with certain pre-setup costs incurred during HY2026.

The Group's revenue is primarily generated from its operations in Singapore. Revenue generated from overseas mainly relates to its pharmaceutical services business segment. In HY2026, Singapore and overseas markets contributed approximately 98.0% and 2.0% of the Group's revenue respectively. In HY2025, Singapore and overseas markets contributed approximately 97.3% and 2.7% of the Group's revenue respectively.



2. Review of performance of the Group (cont'd)

Review of financial position of the Group as at 31 December 2025

Non-current assets

Non-current assets decreased by approximately S\$0.5 million, from S\$24.4 million as at 30 June 2025 to S\$23.9 million as at 31 December 2025 mainly as a net result of the following:

- (a) a decrease in the aggregate carrying value of property, plant and equipment (“PPE”) and ROU assets of approximately S\$0.8 million mainly due to: 1) acquisitions of IT software, computer and medical equipment, a new motor vehicle and renovation works for several clinics, totalling S\$0.7 million; 2) new leases and lease renewals, totalling S\$0.8 million, partially offset by depreciation of S\$2.3 million for PPE and ROU assets;
- (b) a reclassification of the current portion of loan to an associate amounting to S\$150,000;
- (c) an increase in the aggregate carrying value of intangible assets of approximately S\$0.4 million mainly due to additional system development costs of S\$0.6 million, partially offset by amortisation of S\$0.2 million charged during the period; and
- (d) share of results from an associate of approximately S\$94,000 for HY2026.

Current assets

Current assets increased by approximately S\$3.3 million, from S\$66.6 million as at 30 June 2025 to S\$69.9 million as at 31 December 2025. The increase was mainly due to an increase in cash and cash equivalents of S\$2.6 million, an increase in trade and other receivables of approximately S\$0.5 million and an increase in inventories of S\$0.1 million.

Trade and other receivables increased mainly due to higher trade and other receivables in line with higher revenue from managed healthcare solutions, GP clinic services, specialist care services, and mobile and digital health services, partially offset by progress payments received from the Group's YHCMS contract during the period.

Inventories increased mainly to support upcoming pharmaceutical sales and increased GP clinic services.

Other non-financial assets stood at approximately S\$1.1 million as at 31 December 2025, which was comparable to 30 June 2025.

Total equity

Shareholders' equity increased by approximately S\$1.3 million from S\$24.4 million as at 30 June 2025 to S\$25.7 million as at 31 December 2025 mainly as a net result of the following:

- (a) an increase in retained earnings of S\$1.3 million, being net profit attributable to equity holders of the Company of \$1.5 million, partially offset by payment of dividends of S\$0.2 million; and
- (b) value of employee services amounting to S\$41,000 recognised for the Group's Performance Shares awarded on 3 January 2023 pursuant to the Alliance Healthcare Group Performance Share Plan 2022.

Non-controlling interests' deficit increased by approximately S\$0.3 million from S\$0.3 million as at 30 June 2025 to S\$0.6 million as at 31 December 2025, mainly due to net losses attributable to non-controlling interests of S\$0.2 million and payment of dividends of S\$0.1 million to non-controlling interests.



2. Review of performance of the Group (cont'd)

Review of financial position of the Group as at 31 December 2025 (cont'd)

Non-current liabilities

Non-current liabilities decreased by approximately S\$1.5 million, from S\$10.4 million as at 30 June 2025 to S\$8.9 million as at 31 December 2025, mainly due to net repayments of loans and lease liabilities amounting to S\$0.9 million and S\$0.6 million, respectively.

Current liabilities

Current liabilities increased by approximately S\$3.3 million, from S\$56.6 million as at 30 June 2025 to S\$59.9 million as at 31 December 2025, mainly due to the net effect of the following:

- (a) an increase in trade and other payables of approximately S\$2.8 million, largely attributable to the managed healthcare solutions business segment in line with higher business volume during the period;
- (b) an increase in loans and borrowings of approximately S\$0.3 million, net of repayments;
- (c) an increase in income tax payable of approximately \$0.3 million in line with higher profit before tax;
- (d) a net increase in customer advances of approximately S\$0.1 million, recorded under other non-financial liabilities; and partially offset by
- (e) a net decrease in lease liabilities of approximately S\$0.2 million due to repayments during the period.

Review of statement of cash flows for HY2026

The Group generated net cash of approximately S\$6.8 million from operating activities in HY2026, mainly due to operating cash flows before changes in working capital of S\$4.6 million and net working capital inflows of S\$2.5 million, partially offset by income taxes paid of S\$0.3 million.

Net working capital inflows were mainly due to an increase in trade and other payables of S\$2.9 million and an increase in other non-financial liabilities of S\$0.1 million, partially offset by an increase in trade and other receivables of S\$0.4 million and an increase in inventories of S\$0.1 million.

Net cash flows used in investing activities during HY2026 amounted to approximately S\$1.1 million, mainly for acquisitions of PPE and software and system development.

Net cash flows used in financing activities during HY2026 amounted to approximately S\$3.1 million, mainly due to the net effect of the following: payment of lease liabilities of S\$1.8 million, repayment of bank borrowings, financial leases and interest of S\$1.4 million, S\$0.1 million and S\$0.2 million respectively, payment of dividends of S\$0.2 million and S\$0.1 million to equity holders of the Company and non-controlling shareholders respectively; and partially offset by the proceeds from bank borrowings of S\$0.5 million and net proceeds from borrowings from non-controlling shareholder of S\$0.2 million.



3. Where a forecast, or a prospect statement, has been previously disclosed to shareholders, any variance between it and the actual results

There has not been any forecast or prospect statement previously disclosed to shareholders.

4. A commentary at the date of the announcement of the significant trends and competitive conditions of the industry in which the Group operates and any known factors or events that may affect the Group in the next operating period and the next 12 months

Singapore continues to face rising healthcare costs, particularly in the private healthcare sector. This has led to higher insurance premiums and increased healthcare expenses for corporations. Under mounting cost pressures, payers such as health insurers and employers are actively seeking solutions that can better manage costs while maintaining high standards of care for their members and employees.

The Group has been leveraging technology to connect our self-owned clinics with nearly 2,000 partner healthcare facilities, forming an integrated health ecosystem in order to deliver quality care at competitive prices.

Utilisation of our ecosystem continued to grow, with total visits increasing from 1.25 million in FY2024 to over 1.45 million in FY2025, reflecting strong and expanding demand for our network.

Our mobile care subsidiary, JagaMe, currently supports five government hospitals under the Mobile Inpatient Care at Home (“MIC@Home”) programme, which provides hospital-level care to patients who can be safely treated at home. Building on its extensive home-care expertise, JagaMe has expanded into the private sector and is working with hospitals such as Farrer Park Hospital on the “Home Recovery Program”. This initiative aims to shorten hospital stays, improve patient recovery outcomes, and optimise healthcare resource utilisation.

Notwithstanding these opportunities, challenges remain. Macroeconomic uncertainties and rising employee costs may weigh on growth and business performance. The Group will proactively review the performance of individual businesses within our Group to strengthen our financial performance. We will also continue to strengthen and expand our healthcare ecosystem and home-based care solutions to deliver better care at sustainable cost, with greater accessibility for patients.

5. Dividend Information

5(a) Current Financial Period Reported On

Any dividend recommended for the current financial period reported on?

No.

5(b) Corresponding Period of the Immediately Preceding Financial Year

Any dividend declared for the corresponding period of the immediately preceding financial year?

No.

5(c) Date Payable

Not applicable.



5. Dividend Information (cont'd)

5(d) Record Date

Not applicable.

6. If no dividend has been declared/recommended, a statement to that effect and the reason(s) for the decision.

The Board is not recommending any interim dividend in respect of HY2026 as the Board wished to take into consideration the Group's full-year results of operations in view of the Group's capital requirement and current uncertain economic outlook.

7. If the group has obtained a general mandate from shareholders for IPTs, the aggregate value of such transactions as required under Rule 920(1)(a)(ii). If no IPT mandate has been obtained, a statement to that effect.

The Company did not obtain any general mandate from its shareholders in respect of any interested person transaction. The Company did not have any interested person transaction equal to or exceeding S\$100,000 during HY2026.

8. Negative confirmation pursuant to Rule 705(5).

We, Barry Thng Lip Mong and Eugene Wong Hin Sun, being directors of the Company ("Directors"), hereby confirm on behalf of the board of Directors that, to the best of the Directors' knowledge, nothing has come to the attention of the board of Directors which may render the unaudited consolidated financial statements of the Group for the six months ended 31 December 2025 to be false or misleading in any material aspect.

9. Confirmation that the issuer has procured undertaking from all its directors and executive officers (in the format set out in Appendix 7H) under Rule 720(1)

The Company confirms that it has already procured signed undertakings from all of its Directors and relevant executive officers in the format as set out in Appendix 7H of the Catalist Rules in accordance with Rule 720(1) of the Catalist Rules.

10. Acquisition or sale of shares in subsidiaries and/or associated companies under Rule 706(A)

As disclosed in notes 16 and 17 to the condensed interim financial statements, there is no other acquisition and/or sale of shares in any subsidiaries or associated companies of the Group since 30 June 2025 (being the end of the previous period reported on) and up to the date hereof which is required to be reported under Rule 706(A) of the Singapore Exchange Securities Trading Limited ("SGX-ST") Listing Manual Section B: Rules of Catalist ("Catalist Rules").

BY ORDER OF THE BOARD

BARRY THNG LIP MONG
Executive Chairman and CEO
11 February 2026